CymaBay Therapeutics, Inc.
NASDAQ:CBAY
32.48 (USD) • At close March 21, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 31.073 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 3.05 |
| Cost of Revenue
| 0.681 | 0.71 | 0.688 | 0.632 | 0.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 30.392 | -0.71 | -0.688 | -0.632 | -0.8 | 0 | 10 | 0 | 0 | 0 | 0 | 3.05 |
| Gross Profit Ratio
| 0.978 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 80.118 | 67.995 | 64.542 | 35.882 | 83.837 | 58.124 | 18.938 | 15.941 | 17.026 | 15.823 | 4.525 | 9.28 |
| General & Administrative Expenses
| 51.953 | 25.116 | 23.04 | 17.425 | 19.238 | 14.381 | 12.387 | 9.645 | 8.871 | 8.185 | 4.871 | 4.208 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 51.953 | 25.116 | 23.04 | 17.425 | 19.238 | 14.381 | 12.387 | 9.645 | 8.871 | 8.185 | 4.871 | 4.208 |
| Other Expenses
| 1.764 | 0 | 0 | 0 | 5.075 | -3.288 | -5.773 | 0.076 | 11.121 | -7.228 | 0.135 | 0.002 |
| Operating Expenses
| 132.071 | 93.111 | 87.582 | 53.307 | 103.075 | 72.505 | 31.325 | 25.586 | 25.897 | 24.008 | 9.396 | 13.488 |
| Operating Income
| -101.679 | -93.111 | -87.582 | -52.602 | -108.15 | -72.505 | -21.325 | -25.586 | -25.897 | -24.008 | -9.396 | -10.438 |
| Operating Income Ratio
| -3.272 | 0 | 0 | 0 | 0 | 0 | -2.133 | 0 | 0 | 0 | 0 | -3.422 |
| Total Other Income Expenses Net
| -3.691 | -12.89 | -2.416 | 1.616 | 5.342 | -3.695 | -5.773 | 0.076 | 11.121 | -7.228 | 0.135 | 0.002 |
| Income Before Tax
| -105.37 | -106.001 | -89.998 | -50.986 | -102.808 | -72.548 | -27.557 | -26.671 | -15.529 | -31.917 | -10.073 | -11.255 |
| Income Before Tax Ratio
| -3.391 | 0 | 0 | 0 | 0 | 0 | -2.756 | 0 | 0 | 0 | 0 | -3.69 |
| Income Tax Expense
| 0 | 12.89 | 2.583 | -2.321 | -0.572 | 0.293 | -4.693 | 1.413 | 12.034 | -6.473 | 0.957 | 0.843 |
| Net Income
| -105.37 | -118.891 | -92.581 | -48.665 | -102.236 | -72.548 | -27.557 | -26.671 | -15.529 | -31.917 | -10.073 | -11.255 |
| Net Income Ratio
| -3.391 | 0 | 0 | 0 | 0 | 0 | -2.756 | 0 | 0 | 0 | 0 | -3.69 |
| EPS
| -0.99 | -1.35 | -1.3 | -0.71 | -1.53 | -1.25 | -0.79 | -1.14 | -0.82 | -2.65 | -0.72 | -0.8 |
| EPS Diluted
| -0.99 | -1.35 | -1.3 | -0.71 | -1.53 | -1.25 | -0.79 | -1.14 | -0.82 | -2.65 | -0.72 | -0.8 |
| EBITDA
| -100.998 | -91.094 | -86.727 | -53.38 | -97.733 | -71.7 | -26.442 | -25.305 | -14.594 | -31.144 | -9.196 | -10.295 |
| EBITDA Ratio
| -3.25 | 0 | 0 | 0 | 0 | 0 | -2.644 | 0 | 0 | 0 | 0 | -3.375 |